Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

13.50
-0.2300-1.68%
Pre-market: 13.17-0.3300-2.44%06:30 EDT
Volume:1.37M
Turnover:18.55M
Market Cap:1.61B
PE:-12.98
High:13.80
Open:13.62
Low:13.37
Close:13.73
Loading ...

Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand

MT Newswires Live
·
13 Jan

Strong Financial Performance and Growth Prospects Drive Buy Rating for Arcutis Biotherapeutics

TIPRANKS
·
13 Jan

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
13 Jan

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

THOMSON REUTERS
·
12 Jan

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
10 Jan

Arcutis Biotherapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
08 Jan

U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold

Reuters
·
07 Jan

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
07 Jan

BRIEF-Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
07 Jan

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Jan

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks
·
04 Jan

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Simply Wall St.
·
02 Jan

HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target

MT Newswires Live
·
30 Dec 2024

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Reuters
·
30 Dec 2024

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Zacks
·
26 Dec 2024

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)

TIPRANKS
·
25 Dec 2024

Arcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst Ratings

TIPRANKS
·
18 Dec 2024

Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA for Zoryve Cream

MT Newswires Live
·
16 Dec 2024

Arcutis Submits Zoryve® (Roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)

TIPRANKS
·
16 Dec 2024